Condition (MeSH)
Peritonitis
ClinicalTrials.gov lists 117 trials for Peritonitis or a narrower condition beneath it. Wyeth is now a wholly owned subsidiary of Pfizer has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
114 of the 117 trials are tagged with Peritonitis itself; the rest are tagged with a narrower condition beneath it.
When did Peritonitis trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 3 |
| 2021 | 8 |
| 2020 | 6 |
| 2019 | 6 |
| 2018 | 10 |
| 2017 | 6 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 73 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Peritonitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 9 |
| Phase 4 | 16 |
| Not applicable | 38 |
| Observational | 44 |
How many Peritonitis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 6 |
| Active, not recruiting | 1 |
| Completed | 67 |
| Terminated | 10 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Peritonitis trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Wyeth is now a wholly owned subsidiary of Pfizer | 4 |
| Bayer | 3 |
| Pfizer | 3 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
Which drugs are being tested for Peritonitis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Tigecycline | 4 |
| Doripenem | 3 |
| Mupirocin | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| I.V. Meropenem | 3 |
| N Acetylcysteine | 2 |
| PO ciprofloxacin | 2 |
| CHOLECALCIFEROL | 2 |
| Intraperitoneal vancomycin & gentamicin | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Peritonitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| SEPSIS | 45 | 1 |
| Abscess | 37 | 2 |
| Post-operative complications | 21 | 1 |
| Infection | 18 | 2 |
| Respiratory failure | 17 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Peritonitis? (425)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial. | Journal of hepatology | 2025 | Yes |
| High-density lipoproteins alleviate the endotoxin burden in patients with peritonitis and sepsis: The LIPS study. | European journal of clinical investigation | 2025 | Yes |
| Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome. | The Cochrane database of systematic reviews | 2024 | Yes |
| Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial. | The American journal of medicine | 2024 | Yes |
| Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patients. | The Cochrane database of systematic reviews | 2023 | Yes |
Showing 5 of 425 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.